In alignment with these findings, data from the IMMUNOTARGET registry highlighted that among patients with oncogene-driven NSCLC treated with ICIs, those harboring KRAS mutations exhibited the most favorable outcomes, with a response rate of 26% [43]. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.